Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma.

ABSTRACT:

Background

Recurrence is common in glioblastoma multiforme (GBM) because of the infiltrative, residual cells in the tumor margin. Standard therapy for GBM consists of surgical resection followed by chemotherapy and radiotherapy, but the median survival of GBM patients remains poor (~ 1.5 years). For recurrent GBM, anti-angiogenic treatment is one of the common treatment approaches. However, current anti-angiogenic treatment modalities are not satisfactory because of the resistance to anti-angiogenic agents in some patients. Therefore, we sought to identify novel prognostic biomarkers that can predict the therapeutic response to anti-angiogenic agents in patients with recurrent glioblastoma.

Methods

We selected patients with recurrent GBM who were treated with anti-angiogenic

SUBMITTER: Jeon H 

PROVIDER: S-EPMC9893563 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature